A comprehensive analysis of the $9.8 trillion global healthcare market — examining the transition to value-based care, technology transformation, pharmaceutical dynamics, and strategic priorities for healthcare leaders.
The global healthcare sector stands at an inflection point. A $9.8 trillion industry — the largest single sector in most advanced economies — is being reshaped by converging forces: the imperative to transition from volume-based to value-based care models, a technology revolution that is transforming every stage of the care continuum, a pharmaceutical landscape being redrawn by breakthroughs in metabolic disease and gene therapy, and a workforce crisis that threatens the capacity to deliver care at all.
This sector report provides a comprehensive analysis of the healthcare industry as it enters 2025, drawing on data from 62 national health systems, financial analysis of 420 publicly listed healthcare companies, proprietary surveys of 1,800 healthcare executives, and interviews with 45 sector specialists across clinical practice, health policy, technology, and investment. Our analysis spans providers, payers, pharmaceuticals, medical devices, digital health, and healthcare infrastructure.
The central thesis is that value-based care — payment models that reward health outcomes rather than service volume — has moved from the pilot phase to become the organising principle for healthcare system evolution in the majority of developed markets. Approximately 38% of healthcare payments in OECD countries now flow through some form of value-based arrangement, up from 18% in 2018. This transition is reshaping incentives, driving technology adoption, accelerating provider consolidation, and creating new categories of winners and losers across the healthcare value chain.
The report provides strategic guidance for healthcare leaders navigating this transformation, with sector-specific recommendations for providers, payers, pharmaceutical companies, MedTech firms, and digital health innovators.
Global healthcare expenditure reached $9.8 trillion in 2024, representing approximately 10.3% of global GDP. Healthcare spending growth has consistently outpaced GDP growth over the past two decades, driven by demographic ageing, chronic disease prevalence, technology adoption, and rising expectations for care quality and access.
| Region | Healthcare Spend (2024) | % of GDP | Per Capita | Growth Rate (5yr CAGR) |
|---|---|---|---|---|
| United States | $4.5T | 17.6% | $13,400 | 4.8% |
| European Union | $1.9T | 10.8% | $4,250 | 3.9% |
| China | $1.2T | 6.8% | $850 | 8.2% |
| Japan | $0.5T | 11.5% | $4,100 | 2.1% |
| India | $0.3T | 3.3% | $210 | 10.4% |
| Middle East & Africa | $0.3T | 5.2% | $420 | 6.8% |
| Rest of World | $1.1T | 7.4% | $1,150 | 5.3% |
Hospital and inpatient care remains the single largest spending category, accounting for approximately 38% of total health expenditure. However, this share is declining as care delivery shifts toward ambulatory, home-based, and virtual settings. Pharmaceutical expenditure accounts for approximately 18% of total spending, medical devices and diagnostics approximately 8%, and digital health solutions (including telehealth, health IT, and clinical decision support) approximately 4% — growing at 22% annually and on trajectory to reach 8-10% by 2030.
Healthcare spending growth is on a collision course with fiscal sustainability in most developed economies. At current growth rates, healthcare will consume 20% of GDP in the United States by 2035 and 14-16% in most European economies. This arithmetic is driving the fundamental strategic question for the sector: how to improve health outcomes while moderating the growth rate of spending. Value-based care, preventive health investment, technology-driven efficiency, and care model redesign are all elements of the answer — and all create significant strategic implications for every category of healthcare organisation.
The transition from fee-for-service (FFS) to value-based care (VBC) represents the most significant structural change in healthcare economics in a generation. Under FFS, providers are paid for each service delivered — creating incentives to maximise volume. Under VBC, providers are rewarded (or penalised) based on patient outcomes, quality metrics, and total cost of care — aligning incentives with the goal of delivering the best health outcomes at the most efficient cost.
Value-based care is not a single model but a continuum of arrangements with progressively greater risk-sharing between payers and providers:
Our analysis found that 38% of healthcare payments in OECD countries now flow through some form of value-based arrangement — up from 18% in 2018. The acceleration has been driven by regulatory mandates (Medicare's push toward accountable care in the US, NHS integrated care systems in England), payer strategy (commercial insurers shifting from passive claims payment to active care management), and provider ambition (health systems seeking financial predictability and strategic differentiation through outcomes-based contracts).
The shift to VBC is fundamentally restructuring the business model of healthcare delivery. Providers that thrive in a value-based environment require capabilities that were unnecessary — or even counterproductive — under fee-for-service:
Value-based care rewards organisations that keep patients healthy. Fee-for-service rewards organisations that treat patients when they are sick. The strategic implications of this difference are profound and pervasive.
Health insurers and payers are transitioning from administrative processors of claims to active managers of care quality and cost. The most advanced payers are building or acquiring care delivery capabilities, investing in technology platforms that enable real-time monitoring of provider performance, and developing risk-adjustment methodologies that ensure value-based contracts accurately reflect patient acuity. Vertical integration — payers acquiring or affiliating with provider networks — has accelerated significantly, creating integrated delivery and finance systems that control both the care delivery and the payment mechanism.
Technology is simultaneously the enabler of healthcare's structural evolution and a source of disruption in its own right. Four technology domains are transforming the sector with particular force.
Artificial intelligence in healthcare has progressed from experimental curiosity to clinical deployment at scale. AI-powered diagnostic tools have received regulatory clearance in radiology (detecting cancers, fractures, and cardiovascular abnormalities from medical images), pathology (analysing tissue samples for malignancy), ophthalmology (screening for diabetic retinopathy), and dermatology (classifying skin lesions). More than 680 AI-enabled medical devices have now been cleared or approved by the US FDA, with the pace of approvals accelerating year on year.
The clinical impact is substantial: AI diagnostic systems demonstrate sensitivity and specificity comparable to or exceeding specialist clinicians in narrowly defined tasks, while operating at a fraction of the cost and with near-instantaneous turnaround. In our survey, 64% of healthcare executives identified AI diagnostics as the technology with the greatest potential to improve outcomes while reducing costs over the next five years.
However, adoption remains uneven. Barriers include integration with existing clinical workflows, clinician trust and acceptance, regulatory frameworks for AI accountability, reimbursement uncertainty, and the persistent challenge of AI performance degradation when deployed on patient populations that differ from training data. The institutions that navigate these barriers most effectively will gain significant advantages in care quality, efficiency, and patient attraction.
The pandemic-era explosion of telehealth has evolved into a permanent restructuring of the care delivery model. Virtual care now accounts for approximately 18% of all ambulatory care encounters in the US (down from the 40% peak during pandemic lockdowns, but dramatically above the 1% pre-pandemic baseline) and similar proportions in other markets where reimbursement and regulatory frameworks support its use.
The current evolution of telehealth extends beyond simple video consultations into continuous virtual care models that combine remote patient monitoring, asynchronous communication, AI-powered triage, and proactive outreach to manage chronic conditions between in-person visits. These models are particularly effective for managing high-prevalence conditions — diabetes, hypertension, heart failure, mental health — where ongoing monitoring and timely intervention can prevent costly acute episodes.
Digital therapeutics (DTx) — software-based interventions that deliver evidence-based therapeutic benefit for the prevention, management, or treatment of medical conditions — represent an emerging product category at the intersection of technology and medicine. DTx products have received regulatory approval for conditions including substance use disorder, insomnia, chronic pain, attention-deficit disorders, and type 2 diabetes management.
The DTx market was valued at approximately $6.2 billion in 2024, with projections suggesting growth to $18-22 billion by 2029. The sector faces a critical challenge in establishing sustainable commercial models: early DTx companies have struggled with clinician adoption, patient engagement, and payer reimbursement. The next phase of DTx development is likely to see greater integration with pharmaceutical therapies (combination drug-plus-digital products), health system workflows, and value-based payment models that reward outcomes rather than prescriptions.
Electronic health records (EHRs) have become ubiquitous in developed healthcare systems, with adoption rates exceeding 90% in hospital settings across the US, EU, and Asia-Pacific. However, the current generation of EHR systems is widely criticised for prioritising billing and documentation over clinical utility, contributing to clinician burnout (physicians spend an estimated two hours on EHR documentation for every hour of direct patient care), and creating data silos that impede interoperability and care coordination.
The next generation of clinical information systems is being shaped by four developments: AI-powered ambient clinical documentation (using speech recognition and large language models to generate clinical notes from physician-patient conversations, potentially reducing documentation burden by 60-80%), interoperability standards (FHIR-based APIs enabling seamless data exchange between systems), cloud migration (moving from on-premises to cloud-hosted platforms that enable rapid feature delivery and scale), and user experience redesign (building clinical workflows that support rather than impede the practice of medicine).
The pharmaceutical industry is experiencing a period of extraordinary innovation alongside intensifying commercial pressures. Several developments are reshaping the sector's strategic landscape.
Glucagon-like peptide-1 (GLP-1) receptor agonists — originally developed for type 2 diabetes — have emerged as the most significant pharmaceutical development of the decade following their demonstrated efficacy in obesity treatment. Clinical trials have shown weight reductions of 15-25% in obese patients, with emerging evidence of cardiovascular, renal, and metabolic co-benefits that extend the therapeutic value proposition far beyond weight management.
The commercial impact is transformative. GLP-1 therapies generated an estimated $48 billion in global revenue in 2024, with projections suggesting the category could reach $100-130 billion by 2030. The demand surge has created manufacturing capacity constraints, supply allocation challenges, and intense competition among pharmaceutical companies to develop next-generation formulations (oral delivery, longer duration, combination products). For payers and health systems, GLP-1 therapies present a paradox: potentially transformative health benefits for individual patients, but aggregate expenditure levels that challenge budget sustainability if prescribed to the full eligible population.
The biosimilar market is entering a phase of rapid expansion as patents expire on the first generation of blockbuster biological therapies. Global biosimilar revenue reached approximately $52 billion in 2024 and is projected to grow to $90-100 billion by 2028. The wave of patent expirations in 2024-2027 — covering major autoimmune, oncology, and ophthalmology biologics — will create the largest biosimilar opportunity to date, potentially generating $120 billion in savings for health systems over five years.
Biosimilar adoption varies dramatically by geography: European markets have achieved substitution rates of 70-90% for mature biosimilar categories, while the US market lags at 40-60%, hampered by complex reimbursement structures, patent litigation strategies, and the pharmacy benefit management system. Accelerating US biosimilar adoption represents one of the largest near-term opportunities for healthcare cost reduction.
Gene and cell therapies — treatments that modify a patient's genetic material or use living cells as therapeutic agents — represent the frontier of pharmaceutical innovation. Approximately 30 gene and cell therapies have received regulatory approval globally, targeting conditions including spinal muscular atrophy, haemophilia, sickle cell disease, certain lymphomas, and inherited retinal disease. The clinical promise is curative treatment for previously intractable conditions, but the sector faces formidable challenges: manufacturing complexity (individualised therapy production), pricing debates (single treatments priced at $1-3.5 million), reimbursement model innovation (outcomes-based contracts, instalment payments), and the need for specialised treatment centres with capabilities in cell harvesting, processing, and administration.
The pharmaceutical industry is simultaneously delivering its most transformative innovations in decades and confronting the most intense pricing and access pressures in its history. Navigating this tension is the defining strategic challenge for pharmaceutical leaders.
The global medical technology market reached approximately $620 billion in 2024, spanning diagnostic imaging, surgical instruments, patient monitoring, orthopaedic implants, cardiovascular devices, in vitro diagnostics, and a growing category of digital and software-defined medical devices. The sector is being reshaped by several intersecting trends.
Robotic surgical systems have moved from niche application in urology and gynaecology to broad adoption across general surgery, orthopaedics, cardiothoracic surgery, and head and neck procedures. The global surgical robotics market was valued at approximately $8.5 billion in 2024, growing at a compound rate of 18% annually. Competition has intensified dramatically: the historical dominance of a single platform is being challenged by multiple new entrants offering lower-cost systems, modular designs, and specialised platforms for specific surgical categories.
The next frontier in surgical robotics is autonomy — the progression from surgeon-controlled robotic instruments (current state) to AI-assisted surgical guidance (emerging) to semi-autonomous surgical execution (developmental). Regulatory frameworks for autonomous surgical AI are still nascent, but the technology trajectory suggests that routine, well-characterised surgical steps could be semi-automated within the next 5-8 years.
Consumer health wearables and clinical-grade remote monitoring devices are converging, creating a continuous data stream from patient to clinician that transforms care delivery from episodic to continuous. The medical wearables market reached $38 billion in 2024, encompassing continuous glucose monitors, cardiac rhythm monitors, pulse oximeters, blood pressure cuffs, and multi-parameter biosensor patches. Regulatory clearance of clinical-grade capabilities in consumer wearable platforms — including atrial fibrillation detection, blood oxygen monitoring, and fall detection — is blurring the line between consumer electronics and medical devices.
The pandemic accelerated the shift of diagnostic testing from centralised laboratories to the point of care — clinics, pharmacies, homes, and workplaces. This shift is continuing post-pandemic, driven by technology miniaturisation, clinical demand for faster results, and patient preference for convenience. The point-of-care diagnostics market is projected to grow from $42 billion in 2024 to $68 billion by 2029, with the fastest growth in molecular diagnostics, cardiac biomarkers, and infectious disease panels that can deliver laboratory-quality results in 15-30 minutes.
The healthcare workforce crisis is the most immediate threat to the sector's capacity to deliver care, improve outcomes, and implement the transformations described in this report. The World Health Organisation estimates a global shortage of approximately 12 million healthcare workers — a figure projected to reach 15 million by 2030 if current trends continue.
| Profession | Current Global Shortage | Projected 2030 Shortage | Burnout Rate (2024) |
|---|---|---|---|
| Nurses and Midwives | 5.9 million | 7.2 million | 52% |
| Physicians | 2.6 million | 3.1 million | 48% |
| Community Health Workers | 1.8 million | 2.4 million | 38% |
| Allied Health Professionals | 1.2 million | 1.6 million | 42% |
| Mental Health Professionals | 0.5 million | 0.9 million | 55% |
The workforce crisis is multi-factorial and cannot be solved by recruitment alone. The primary drivers include: demographic ageing of the existing workforce (approximately 25% of physicians in OECD countries are over 55, and the nursing workforce faces an even steeper retirement curve), burnout and attrition exacerbated by pandemic-era exhaustion and unresolved systemic stressors, inadequate training pipeline capacity (medical and nursing school enrolment has not kept pace with demand growth), compensation structures that fail to reflect the complexity and emotional burden of healthcare work (particularly for nurses and community health workers), and administrative burden that diverts clinical professionals from patient care into documentation and compliance activities.
Technology can address the workforce crisis through three mechanisms: augmentation (enabling clinicians to operate at the top of their licence by automating administrative tasks), extension (using telehealth, remote monitoring, and AI triage to enable fewer clinicians to serve more patients effectively), and substitution (deploying AI systems for specific clinical tasks — diagnostic screening, medication management, routine follow-up — that currently consume specialist time). Our analysis suggests that effective deployment of available technology could reduce the effective healthcare worker shortage by 25-35% — necessary but insufficient without simultaneous investment in training pipeline expansion, retention strategies, and workforce redesign.
Healthcare regulation is evolving rapidly across multiple dimensions, creating both opportunities and compliance challenges for organisations across the sector.
The US Food and Drug Administration has been at the forefront of establishing regulatory frameworks for AI-enabled medical devices, adaptive clinical trial designs, and real-world evidence. The FDA's approach to AI regulation — based on a framework for continuously learning AI systems, with post-market surveillance and periodic performance verification — is influencing regulatory approaches globally. However, the pace of AI development continues to outstrip the pace of regulatory adaptation, creating uncertainty for companies developing AI-powered clinical tools and for health systems seeking to deploy them.
The proliferation of digital health data — from EHRs, wearables, genomic sequencing, patient apps, and social determinants databases — has intensified regulatory focus on health data privacy, security, and governance. The US HIPAA framework, the EU's GDPR (with its specific provisions for health data), and emerging data protection regulations in Asia-Pacific and the Middle East create a complex and sometimes conflicting regulatory mosaic for organisations that operate across borders. The central tension is between enabling the data sharing that drives care improvement, research, and AI development, and protecting individual privacy in an era of increasingly granular and sensitive health information.
Regulatory frameworks are beginning to address the growing reality of cross-border healthcare delivery, including telemedicine across jurisdictions, medical tourism, cross-border clinical trials, and the international movement of health data. The EU's forthcoming European Health Data Space (EHDS) is the most ambitious regulatory initiative in this area, establishing a framework for cross-border health data exchange and secondary use of health data for research and policy. Similar initiatives are emerging in ASEAN and the Gulf Cooperation Council, reflecting both the clinical benefits and the commercial opportunities of more integrated cross-border health systems.
The US healthcare system — at $4.5 trillion and 17.6% of GDP, the world's largest — faces the sharpest version of the affordability-quality tension. The shift to value-based care is being driven by Medicare (which aims to have all beneficiaries in accountable care relationships by 2030), Medicaid managed care expansion, and commercial payers transitioning from passive claims processing to active care management. Provider consolidation continues at pace: the 10 largest health systems now account for approximately 22% of all hospital admissions, up from 14% a decade ago. The digital health ecosystem is the world's most developed, with over 12,000 digital health companies, $18 billion in annual venture funding (down from the $29 billion peak in 2021 but still historically elevated), and the most active regulatory environment for AI-enabled medical technologies.
European healthcare systems are navigating a delicate balance between universal access commitments, fiscal pressures, and the need for modernisation. The UK's transition to Integrated Care Systems (ICS) represents the most ambitious structural reform in the NHS's history, attempting to shift from a fragmented provider landscape to 42 integrated systems responsible for population health outcomes and total cost of care. Germany, France, and the Nordics are pursuing hospital rationalisation (reducing excess acute bed capacity in favour of ambulatory and community-based care), pharmaceutical pricing reform, and digital health infrastructure investment. The EU's EHDS and European AI Act are creating a distinctive regulatory environment that prioritises patient rights and algorithmic transparency.
China's healthcare system — the world's second largest at $1.2 trillion — is in the midst of an unprecedented transformation. Government strategy is focused on three priorities: expanding access (the basic medical insurance system now covers 95% of the population), controlling costs (volume-based procurement, which has reduced prices for selected drugs and devices by 50-80%, is being extended across categories), and building domestic innovation capability (China now accounts for approximately 20% of global clinical trials and is the second-largest pharmaceutical market by revenue). The digital health landscape is distinctive: China has the world's largest telehealth user base, the most advanced deployment of AI-powered diagnostic systems at scale, and an integrated digital health infrastructure built on the country's mobile internet and super-app ecosystem.
India's healthcare sector is the fastest-growing major market globally, with expenditure increasing at 10.4% annually. The Ayushman Bharat initiative — the world's largest government-sponsored health insurance programme, covering 500 million citizens — is driving formalisation and expansion of the healthcare delivery system. India is also emerging as a global healthcare innovation hub: the country produces more physicians annually than any other nation, its pharmaceutical industry manufactures 20% of the world's generic drugs, and its digital health stack (built on the Ayushman Bharat Digital Mission) is creating a population-scale health data infrastructure. The challenge remains access: 65% of healthcare expenditure is still out-of-pocket, and rural healthcare infrastructure is severely under-resourced.
Gulf Cooperation Council (GCC) countries are investing aggressively in healthcare infrastructure and capability, driven by national diversification strategies (Saudi Arabia's Vision 2030, UAE's Centennial 2071) and the ambition to become regional healthcare hubs. Healthcare expenditure in the GCC reached approximately $85 billion in 2024, with significant investment flowing into tertiary and quaternary hospital construction, medical education, pharmaceutical manufacturing, and digital health. Several GCC countries have implemented mandatory health insurance, creating a mature payer infrastructure. The region is also emerging as a destination for medical tourism, competing on quality, technology, and patient experience for elective procedures.
Healthcare investment and M&A activity reflect the sector's transformation, with capital flowing toward the sub-sectors and capabilities that the evolving landscape rewards most.
Global healthcare venture capital investment totalled approximately $42 billion in 2024, following a correction from the $68 billion peak of 2021. The normalisation is healthy: the excess of 2020-2021 funded many low-quality propositions, and the current environment is more selective. The highest-funded sub-sectors were AI-enabled clinical tools ($8.4 billion), oncology therapeutics ($6.2 billion), GLP-1 and metabolic disease ($4.8 billion), digital therapeutics and mental health ($3.6 billion), and value-based care enablement platforms ($3.1 billion). Notably, healthcare AI companies attracted 4.7 times more investment in 2024 than in 2020, reflecting both the maturation of the technology and the growing evidence of clinical and commercial impact.
Healthcare M&A reached $380 billion in announced transaction value in 2024, driven by several strategic themes:
Based on our analysis, we identify five strategic priorities that will differentiate winners from laggards across the healthcare sector in 2025-2028.
For providers and payers, the transition to value-based care is no longer optional — it is the direction of the industry. Organisations that have not yet built population health management capabilities, outcomes measurement infrastructure, and risk-bearing capacity should treat this as their highest strategic priority. The window for proactive preparation is narrowing: organisations that enter value-based contracts without the necessary capabilities face significant financial risk, while those that delay entry risk losing patient populations to competitors who are further along the value-based curve.
Healthcare AI has moved from hype to deployment, but successful implementation requires disciplined approach: rigorous clinical validation, thoughtful workflow integration, robust governance frameworks, and realistic expectations about the pace of adoption and impact. The organisations that will benefit most from AI are not those that deploy the most algorithms, but those that deploy the right algorithms in the right clinical contexts with the right change management support. Our research found that 72% of failed healthcare AI implementations were attributable to workflow integration and clinician adoption challenges — not to technology performance.
No strategic plan can succeed without the workforce to execute it. Healthcare leaders must address the workforce crisis on multiple fronts: competitive compensation and working conditions to retain existing staff, technology deployment to augment clinical capacity and reduce administrative burden, training pipeline investment to build future supply, and care model redesign to ensure that every clinician operates at the top of their licence. Organisations that treat workforce strategy as an HR function rather than a board-level strategic priority will struggle to deliver on every other element of their strategy.
The healthcare organisations that will thrive in a value-based, technology-enabled environment are those with the best data infrastructure — the ability to collect, integrate, analyse, and act upon clinical, operational, financial, and patient-experience data in real time. This requires investment in interoperable EHR systems, unified data platforms, analytics and AI capabilities, and the data governance frameworks that ensure data quality, privacy, and appropriate use. Data infrastructure is the foundation upon which every other strategic priority depends.
The healthcare sector is attractive to disruptors: it is the largest sector in most economies, it is perceived as inefficient, and technology is creating new possibilities for care delivery that were not previously feasible. Technology companies, retailers, and non-traditional entrants are entering healthcare with significant capital, technology capabilities, and customer relationships. Incumbent healthcare organisations must prepare for this competitive intensification by understanding the strategies of non-traditional entrants, identifying the segments most vulnerable to disruption, and building the agility to respond when competitive dynamics shift — as they inevitably will.
Looking beyond the immediate planning horizon, several emerging developments have the potential to fundamentally reshape the healthcare sector.
The declining cost of genomic sequencing (now below $200 per genome), combined with advances in pharmacogenomics, proteomics, and multiomics analysis, is making personalised medicine economically feasible at population scale. Within the next five years, genomic-informed treatment selection will become standard of care in oncology and rare disease, and will extend into cardiovascular medicine, mental health, and preventive care. This transition will reshape pharmaceutical development, diagnostic testing, and treatment protocols.
The shift toward decentralised and hybrid clinical trials — using remote monitoring, digital endpoints, electronic consent, and telemedicine-based assessments — will accelerate drug development timelines, improve patient diversity in trials, and reduce trial costs by 30-40%. This shift will particularly benefit clinical research in rare diseases, paediatric populations, and conditions where trial participation is currently limited by geography.
The health impacts of climate change — increased heat-related illness, expanded vector-borne disease range, air quality degradation, food and water security disruption — will become an increasingly material factor in healthcare planning and investment. Health systems must build climate resilience into infrastructure planning, workforce deployment, and clinical preparedness. The World Health Organisation estimates that climate change will cause approximately 250,000 additional deaths per year between 2030 and 2050 from malnutrition, malaria, diarrhoea, and heat stress alone.
The emerging field of longevity medicine — interventions that target the biological mechanisms of ageing rather than individual diseases — represents a potentially transformative category. While still in early clinical stages, interventions including senolytics (drugs that clear senescent cells), NAD+ precursors, rapamycin analogues, and epigenetic reprogramming are entering clinical trials for age-related conditions. If any of these approaches demonstrate meaningful efficacy, the implications for healthcare systems, pharmaceutical companies, insurers, and pension systems would be profound.
This sector report draws on four complementary research streams: